Patents by Inventor Alfred Hahn
Alfred Hahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170008959Abstract: The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor mulitimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.Type: ApplicationFiled: January 12, 2016Publication date: January 12, 2017Inventors: Alfred Hahn, Ralf Loebbert, Nicole Teusch, Achim Möller, Ulrich Ebert, Martin Schmidt
-
Patent number: 9296697Abstract: The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.Type: GrantFiled: August 23, 2006Date of Patent: March 29, 2016Assignees: Abbott Laboratories, AbbVie Deutschland GmbH & Co. KGInventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Francisco Javier Garcia-Ladona, Wolfgang Wernet, Alfred Hahn
-
Patent number: 9291621Abstract: The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.Type: GrantFiled: January 18, 2006Date of Patent: March 22, 2016Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Alfred Hahn, Ralf Loebbert, Nicole Teusch, Achim Möller, Ulrich Ebert, Martin Schmidt
-
Publication number: 20160032000Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: May 22, 2015Publication date: February 4, 2016Inventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller
-
Patent number: 9109026Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: June 3, 2009Date of Patent: August 18, 2015Assignee: ABBVIE, INC.Inventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller
-
Publication number: 20150183867Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 11, 2015Publication date: July 2, 2015Inventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller
-
Patent number: 8921406Abstract: The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.Type: GrantFiled: August 21, 2006Date of Patent: December 30, 2014Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Andreas Haupt, Francisco Javier Garcia-Ladona, Alfred Hahn
-
Patent number: 8791148Abstract: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.Type: GrantFiled: November 22, 2011Date of Patent: July 29, 2014Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Torsten Arndt, Thorsten Oost, Wilfried Lubisch, Wilfried Homberger, Liliane Unger, Juliana Ruiz Caro, Alfred Hahn
-
Patent number: 8686002Abstract: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.Type: GrantFiled: August 21, 2006Date of Patent: April 1, 2014Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Francisco Javier Garcia-Ladona, Alfred Hahn
-
Patent number: 8486931Abstract: The present invention relates to compounds of the general formula (I) in which A, B, R1, R2 and Het have the meaning given in claim 1; Y is a bivalent group of the formula in which D is C1-C3-alkylene, where D may have a substituent R5; R3 is hydrogen, C1-C8-alkyl or together with R4 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, and R4 is hydrogen, C1-C8-alkyl or together with R3 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, where R5 together with R5a, where present, are a bond or C1-C3-alkylene; and where one of the following conditions is satisfied: R3 together with R4 is C1-C3-alkylene which may have a radical R5a; or R3 together with R5 is C1-C3-alkylene; or R4 together with R5 is C1-C3-alkylene where the radical A is different from phenyl when the radical B is phenyl or naphthyl; and medicaments which comprise such compounds and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent and/oType: GrantFiled: February 29, 2008Date of Patent: July 16, 2013Assignee: Abbott GmbH & Co. KGInventors: Herve Genesle, Thorsten Oost, Charles W. Hutchins, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch, Astrid Netz, Alfred Hahn
-
Publication number: 20120213476Abstract: A connection device for an optical fibre comprises a housing and a first optical fibre arranged therein. In this case, the first optical fibre is fixed in the housing by a stopper.Type: ApplicationFiled: August 10, 2010Publication date: August 23, 2012Applicant: TYCO ELECTRONICS AMP GmbHInventors: Bodo Bimboese, Joachim Alfred Hahn, Guido Van De Burgt
-
Patent number: 8242102Abstract: The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R is a moiety of the formula wherein A, R1 to R4 are as defined in the claims and the specification, n is 0, 1 or 2; m is 0, 1, 2 or 3; Ra, Rb are independently selected from the group consisting of halogen, CN, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C(O)Raa, C(O)NRccRbb and NRccRbb; X is CH2, C(O), S, S(O) or S(O)2; which is located in the 3- or 4-position of the quinoline ring; Ar is a radical Ar1, Ar2—Ar3 or Ar2—O—Ar3, wherein Ar1, Ar2 and Ar3 are each independently selected from the group consisting of aryl or hetaryl wherein aryl or hetaryl moieties may be unsubstituted or may carry 1, 2, 3 substituents Rx, wherein and physiologically tolerated acid addition salts and the N-oxides thereof.Type: GrantFiled: March 23, 2008Date of Patent: August 14, 2012Assignee: Abbott GmbH & Co. KGInventors: Sean Colm Turner, Andreas Haupt, Wilfried Braje, Udo Lange, Karla Drescher, Karsten Wicke, Liliane Unger, Mario Mezler, Wolfgang Wernet, Alfred Hahn, legal representative, Matthias Mayrer
-
Publication number: 20120172335Abstract: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.Type: ApplicationFiled: November 22, 2011Publication date: July 5, 2012Inventors: Torsten Arndt, Thorsten Oost, Wilfried Lubisch, Wilfried Homberger, Liliane Unger, Juliana Ruiz Caro, Wolfgang Wernet, ALfred Hahn
-
Patent number: 8119676Abstract: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.Type: GrantFiled: August 24, 2007Date of Patent: February 21, 2012Assignee: Abbott GmbH & Co. HGInventors: Torsten Arndt, Thorsten Oost, Wilfried Lubisch, Wolfgang Wernet, Alfred Hahn, legal representative, Wilfried Hornberger, Liliane Unger, Juliana Ruiz Caro
-
Publication number: 20110207788Abstract: The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.Type: ApplicationFiled: August 21, 2006Publication date: August 25, 2011Inventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Andreas Haupt, Francisco Javier Garcia-Ladona, Wolfgang Wernet, Alfred Hahn
-
Publication number: 20110009380Abstract: The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R is a moiety of the formula wherein A, R1 to R4 are as defined in the claims and the specification, n is 0, 1 or 2; m is 0, 1, 2 or 3; Ra, Rb are independently selected from the group consisting of halogen, CN, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C(O)Raa, C(O)NRccRbb and NRccRbb; X is CH2, C(O), S, S(O) or S(O)2; which is located in the 3- or 4-position of the quinoline ring; Ar is a radical Ar1, Ar2—Ar3 or Ar2—O—Ar3, wherein Ar1, Ar2 and Ar3 are each independently selected from the group consisting of aryl or hetaryl wherein aryl or hetaryl moieties may be unsubstituted or may carry 1, 2, 3 substituents Rx, wherein and physiologically tolerated acid addition salts and the N-oxides thereof.Type: ApplicationFiled: March 23, 2008Publication date: January 13, 2011Applicant: ABBOTT GMBH & CO. KGInventors: Sean Colm Turner, Andreas Haupt, Wilfried Braje, Udo Lange, Karla Drescher, Karsten Wicke, Liliane Unger, Mario Mezler, Wolfgang Wernet, Alfred Hahn, Matthias Mayrer
-
Publication number: 20100226915Abstract: The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor mulitimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.Type: ApplicationFiled: January 18, 2006Publication date: September 9, 2010Inventors: Alfred Hahn, Ralph Loebbert, Nicole Teusch, Achim Möller
-
Publication number: 20100041698Abstract: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.Type: ApplicationFiled: August 21, 2006Publication date: February 18, 2010Inventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Francisco Javier Garcia-Ladona, Wolfgang Wernet, Alfred Hahn
-
Publication number: 20090304693Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: June 3, 2009Publication date: December 10, 2009Applicant: ABBOTT LABORATORIESInventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller
-
Patent number: 6291091Abstract: A continuous method manufactures a laminated electrolyte and electrode assembly (“laminated assembly”) comprising at least one pre-formed electrode layer, at least one catalyst layer and at least one electrolyte layer for an electrochemical cell. The method comprises forming at least one of the catalyst or electrolyte layers in situ and using it as a laminating medium. The method produces a laminated assembly in a continuous sheet, which may be later cut to size and shape for use in electrochemical cells. The method may comprise co-extruding granular catalyst and/or electrolyte materials. In one embodiment, the catalyst and electrolyte layers are co-extruded. The co-extruded tri-layer extrusion is laminated with immediately adjacent pre-formed electrode layers. In another embodiment the catalyst layer is extruded and the catalyst layer acts as the laminating medium between immediately adjacent pre-formed electrode and electrolyte layers.Type: GrantFiled: December 18, 1998Date of Patent: September 18, 2001Assignee: Ballard Power Systems Inc.Inventors: Christine Preischl, Peter Hedrich, Alfred Hahn